Session Type: Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in the treatment of RA-ILD, especially if it is initiated early during the ILD. Our objective was to compare the efficacy of ABA in RA-ILD patients according to ILD duration.
Methods: National multicenter study of 509RA-ILD patients treated with ABA. Patients with ABA initiation early in the disease (during the first 6 months since ILD diagnosis) were compared to those in whom ABA was started after 2 years of ILD diagnosis (“early” vs. “late” group, respectively). We analyzed in the 2 groups the following outcomes: a) forced vital capacity (FVC), b) diffusing capacity of the lungs for carbon monoxide (DLCO), c) chest high resolution computed tomography (HRCT), d)dyspnea (modified Medical Research Council scale), and e) arthritis activity (DAS28-ESR or clinical records).
Results: A total of 216 patients were included in the “early” group and 165 patients in the “late” group. Baseline demographic and clinical characteristics are shown in Table 1. Mean baseline values of FVC were significantly higher in the “early” group. The evolution of FVC and DLCO for 48 months is shown in Figure 1. Both parameters remained stable during 48 months of ABA therapy, with statistically significant differences found in case of FVC (although lower stable values of FVC in the “late” group). Available chest HRCT images improved/ stabilized in 76% and 54% of patients in the “early” and “late” group, respectively. Stabilization or improvement of dyspnea was found in most patients of both groups.
Conclusion: Our study suggests a window of opportunity for the treatment of RA-ILD patients with ABA. However, treatment with ABA at any time of the course in the ILD seems to prevent interstitial lung progression.
To cite this abstract in AMA style:Serrano-Combarro A, Atienza-Mateo B, Ibarrola-Paino l, Casafont-Sole I, Melero-Gonzalez R, Perez Linaza A, Castañeda S, Ortega Castro R, Mena Vazquez N, Vegas Revenga N, Dominguez Casas L, Peralta C, Pérez-Sandoval T, Perez-Albadalejo L, Lopez-Sanchez R, MANZANO CANABAL M, Brandy-Garcia A, Lopez-Viejo P, Bonilla G, Maiz-Alonso O, carrasco-Cubero C, Garijo Bufort M, Moreno M, Urruticoechea A, Ordonez-Palau S, Gonzalez-Montagut Gomez C, Garcia-Valle a, Dios Jimenez De Aber J, Lozano F, Vazquez-Rodriguez T, Martin-Lopez M, Blanco-Madrigal J, Fernández-Lozano D, Brana Abascal I, Loarce-Martos J, Giner-Serret E, Ruiz-Esquide V, ventin-Rodriguez C, Rodriguez-lopez M, Andujar-Brazal P, Fernandez-Melon J, Lopez L, Fernandez-Diaz c, Loricera J, Ferraz Amaro I, Ferrer D, Blanco R, Collaborative Group Members O. Window of Opportunity in the Treatment of Rheumatoid Arthritis-Interstitial Lung Disease with Abatacept. National Multicenter Study of 509 Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/window-of-opportunity-in-the-treatment-of-rheumatoid-arthritis-interstitial-lung-disease-with-abatacept-national-multicenter-study-of-509-patients/. Accessed .
« Back to ACR Convergence 2023
ACR Meeting Abstracts - https://acrabstracts.org/abstract/window-of-opportunity-in-the-treatment-of-rheumatoid-arthritis-interstitial-lung-disease-with-abatacept-national-multicenter-study-of-509-patients/